Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.

Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high ...

A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an ...

Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients ...